NEOD 001

Drug Profile

NEOD 001

Alternative Names: NEOD001

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Neotope Biosciences; Onclave Therapeutics
  • Developer Prothena
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid fibril protein AL inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyloid light-chain amyloidosis

Most Recent Events

  • 17 May 2017 Prothena Therapeutics plans a phase II trial for Amyloid light chain amyloidosis (Treatment-experienced) (NCT03154047)
  • 24 Feb 2017 Prothena has patent protection for NEOD 001 in (Protehna's form 10-K, filed in February 2017)
  • 02 Aug 2016 Efficacy data from a phase I/II trial in Amyloid light-chain amyloidosis released by Prothena
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top